U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Takeda』s Investigational Compound, TAK-994, an Oral Orexin Agonist in Clinical Development for Narcolepsy Type 1 (NT1)
CAMBRIDGE, Mass. & OSAKA, Japan -- (BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (「Takeda」) today announced that the U.S. Food and Drug Administration (FDA......
